Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Novartis
Repare Therapeutics
Suzhou Zanrong Pharma Limited
Merck Sharp & Dohme LLC
Bridge Biotherapeutics, Inc.
ESSA Pharmaceuticals
MedPacto, Inc.
Oblato, Inc.
Novartis
EMD Serono
Takeda
Bayer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Eli Lilly and Company
Arog Pharmaceuticals, Inc.
TetraLogic Pharmaceuticals
Bayer
Incyte Corporation